BTIG Reiterates Neutral Rating on Senseonics Holdings (SENS)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
Go back to BTIG Reiterates Neutral Rating on Senseonics Holdings (SENS)
September 17, 2024 8:29 AM EDT
Stifel analyst Mathew Blackman reiterated a Buy rating and $2.50 price target on Senseonics Holdings (NYSE: SENS).
The analyst comments "This morning, SENS announced on-time FDA approval of Eversense 365-day with iCGM status; a 4Q24 US launch timeline was also re-affirmed. Importantly, approval... More
September 17, 2024 7:04 AM EDT
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes and Ascensia Diabetes Care, a global diabetes care company, today announced that the US Food and Drug Administration (FDA) has cleared the next-generation Eversense® 365 CGM system for people with Type 1 and Type 2 diabetes aged 18 years and older. Eversense 365 is the worlds first One Year CGM system, representing a significant breakthrough in diabetes technology and management.
The approval of Eversense 365 represents a significant leap in... More
